Search results
EAN 2024: encouraging analyses of pridopidine Healey ALS platform trial
Clinical Trials Arena· 1 hour agoHowever, outside of the pre-specified and additional analyses, primary and secondary key analyses in...
Breakthrough In Lung Cancer Treatment, Study Finds
Latest India News· 1 day agoThe research, which was just published in JAMA Oncology, showed that IMRT had comparable survival rates while having fewer adverse effects. A prospective...
UPSC Essentials | Mains answer practice — GS 2 : Question on India’s performance in Global Gender...
Indian Express· 5 days agoDiscuss the variables that influence India’s performance and offer ways to improve its gender parity...
Sedentary, non-coffee drinkers at 60% more risk of dying, study finds - ET HealthWorld
The Economic Times· 6 days agoNew Delhi: Non-coffee drinkers who sat for six or more hours a day were at almost 60 per cent higher...
The state of oligonucleotide therapeutic manufacturing: what biopharmaceutical players need to know
Pharmaceutical Technology· 40 minutes agoIn the genomic medicine toolbox, oligonucleotide therapeutics offer highly specific and effective...
Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug
Clinical Trials Arena· 6 days agoIt found that the study is “unlikely to meet its primary objective of prolonging event-free survival...
Optimizing Solar Panel Manufacturing Efficiency and Reliability
POWER Magazine· 5 hours agoWhether you’re a longtime solar panel maker or just embarking on a business plan, it’s easy to...
Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer
Pharmaceutical Technology· 6 days agoAn ongoing controlled, randomised Phase IIb clinical trial is assessing the safety and efficacy of...
Extreme weather, erratic rain hurt marginal farmers: Report
Hindustan Times· 6 days agoNearly 50% of rice and wheat farmers surveyed for the analysis reported crop loss due to the last...
BMS expands Krazati’s FDA label to include colorectal cancer
Clinical Trials Arena· 6 days agoAt a median follow-up of 7.8 months, the participants in the Lumakaras/Vectibix combination therapy...